SCHEMBL4777639

SCHEMBL4777639

Cc1ccc(C(C(N)=O)c2ccc(N(Cc3ccccc3Cl)S(C)(=O)=O)cc2)o1

nearest known ligand 0.46

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.44
ALDH1A1 P00352 3/20 0.43
MAPT P10636 3/20 0.40
RECQL P46063 2/20 0.38
TP53 P04637 1/20 0.38
HPGD P15428 2/20 0.38
NPSR1 Q6W5P4 2/20 0.38
POLB P06746 3/20 0.37
MEN1 O00255 3/20 0.36
KMT2A Q03164 3/20 0.36
LMNA P02545 1/20 0.36
KDM4E B2RXH2 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4771116 0.81 GAA (0.43) GAAALDH1A1MAPTRECQLTP53
SCHEMBL4777345 0.80 GAA (0.55) GAAALDH1A1MAPTRECQLTP53
SCHEMBL4769726 0.79 POLB (0.44) GAAALDH1A1MAPTTP53POLB
SCHEMBL4776388 0.78 ALDH1A1 (0.45) GAAALDH1A1MAPTNPSR1
SCHEMBL4831822 0.76 GAA (0.47) GAAALDH1A1MAPTTP53
SCHEMBL4771381 0.76 GAA (0.41) GAAALDH1A1MAPTRECQLTP53
SCHEMBL4777536 0.76 GAA (0.58) GAAALDH1A1MAPTRECQLHPGD
SCHEMBL4775063 0.75 GAA (0.40) GAAALDH1A1MAPTTP53NPSR1
SCHEMBL4776713 0.75 GAA (0.46) GAAALDH1A1MAPTRECQLTP53
SCHEMBL4771209 0.73 GAA (0.39) GAAALDH1A1MAPTTP53MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1942888-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS Cytokinetics, Inc. (US) 2008-07-16 EP claimed
US-20070135435-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INCORPORATED 2007-06-14 US claimed
WO-2007056078-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS CYTOKINETICS, INC. (US) 2007-05-18 WO claimed
EP-1942888-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS Cytokinetics, Inc. (US) 2008-07-16 EP disclosed
US-20070135435-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INCORPORATED 2007-06-14 US disclosed
WO-2007056078-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS CYTOKINETICS, INC. (US) 2007-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135435-A1 Certain chemical entities, compositions, and methods KIF5B, KIF2C, PLK1 GAA 466/4885ALDH1A1 2159/4885MAPT 294/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.